Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406507 · ClinicalTrials.gov registry record · Phase 3
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
A Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
- 9
- Study locations
NCT03406507 is a Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 13 participants, below the 264-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT03406507, a Phase 3 study of Paroxysmal Nocturnal Hemoglobinuria, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
Conditions Studied
Interventions
- BIOLOGICAL Ravulizumab
Study Locations (9)
Other
- Clinical Trial Site - Paris
- Clinical Trial Site - Utrecht
- Clinical Trial Site - Oslo
- Clinical Trial Site - Moscow
- Clinical Trial Site - Saint Petersburg
- Clinical Trial Site - Leeds
- Clinical Trial Site - London
Georgia
- Clinical Trial Site - Atlanta
Wisconsin
- Clinical Trial Site - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406507
The ClinicalTrials.gov registry entry for NCT03406507 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (95% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT03406507 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Other, Georgia, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03406507 about?
NCT03406507 is a clinical study titled "A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria". The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).
What is the current status of trial NCT03406507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2018-02-22. Estimated completion is 2022-08-25.
What conditions does trial NCT03406507 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
What interventions are being tested in trial NCT03406507?
The interventions under investigation include: Ravulizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03406507?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03406507 being conducted?
This trial has 9 study locations across Georgia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
COMPLETED · Phase 3
-
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.